Biocytogen strengthens its partnership with Merck


Biocytogen Pharmaceuticals Co., Ltd. has signed a worldwide license agreement with Merck for the use of Biocytogen’s RenMice TM platform. Under the terms of the agreement, Merck will have full access to Biocytogen’s RenMice TM platform for the discovery and development of fully human antibody therapies for an unlimited number of drug targets. Merck will assume all clinical development, manufacturing and marketing activities, and will pay Biocytogen milestone payments in accordance with development and regulations. The official agreement was reached after an initial evaluation period.

“ This agreement provides Merck with one of the most advanced fully human antibody discovery platforms. We are pleased that Merck has recognized the potential of our RenMice™ platform to accelerate the development of antibodies for novel and complex targets.”

Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen


What Biocytogen Do

Global biotechnology company Biocytogen Pharmaceuticals (Beijing) Co., Ltd. focuses on the study and creation of new antibody-based medications. Through the utilisation of RenMice TM for completely human antibody identification, in vivo drug efficacy testing platforms, and extensive clinical development expertise, the business has shortened the drug development process. The Biocytogen RenMice TM HiTS platform has resulted in partnerships with dozens of partners worldwide and intends to create novel antibodies with the potential to be the first and/or best for more than 1,000 targets. Twelve main items make up the company’s portfolio, two of which are now undergoing phase II multi-regional clinical studies and two others are in phase I. Based in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston (USA) and Heidelberg (Germany).

What Merck Do

Healthcare, life science, and electronics sectors are all represented by Merck, a leader in science and technology. An estimated 60,000 workers strive to improve the quality of life for millions of people by developing more enjoyable and sustainable lifestyles. The company is active in a wide range of fields, including developing gene editing technologies, identifying novel approaches to treating the most difficult diseases, and developing smarter products. Sales for Merck totaled €19.7 billion in 2021 across 66 nations.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advancements. This is how Merck has thrived since its founding in 1891. The founding family remains the majority shareholder of the publicly traded company. Merck owns the worldwide rights to the Merck name and brand. The only exceptions are the United States and Canada, where Merck’s business segments operate as EMD Serono for healthcare, MilliporeSigma for life sciences, and EMD Electronics for electronic.

In no way should the press release text that was translated be regarded as official. The press release in its original language is the only version that is truly authentic. Always comparing the translation to the original text will establish a standard.

Next Post

ABEC announces an $11 million investment in a new manufacturing facility in North Carolina

A $10 million investment will be made by ABEC, a global provider of technical solutions and services for the production of biotech goods, to increase its disposable container (DC) manufacturing capacity. Your CSR biomanufacturing solutions should only be used once. The business has a facility in Wilson, North Carolina, that […]